Skip to content

Imaging genomics Exploration in patients with hereditary cardiomyopathy Phase II clinical study

Imaging genomics Exploration in patients with hereditary cardiomyopathy Phase II clinical study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400090255
Enrollment
Unknown
Registered
2024-09-26
Start date
2024-09-26
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary cardiomyopathy

Interventions

Patients with hereditary cardiomyopathy:NA

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 90 Years

Inclusion criteria

Inclusion criteria: 1. Clinically and radiologically diagnosed patients with cardiomyopathy and two or more relatives in the family, including the proband, have been diagnosed as patients with cardiomyopathy. 2. Patients with cardiomyopathy were included in the following categories: hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy (RCA), left ventricular insufficiency (LVNC), cardiac amyloidosis, Danon's disease, Fabre's disease and their first-degree relatives. 3. Age: 0-90 years old.

Exclusion criteria

Exclusion criteria: 1. Patients refused to participate or were unable to complete the interview

Design outcomes

Primary

MeasureTime frame
Cardiac magnetic resonance;Echocardiography;Second generation sequencing;Single cell sequencing;Family history;Genealogy chart;Clinical outcomes and outcomes (Hospital readmission due to heart failure, ICD implantation, medical chemical ablation or surgical Morrow myocardial resection, thromboembolism, pacemaker discharge or syncope recovery after resuscitation, heart transplant, death, cardiovasculary-related death);

Secondary

MeasureTime frame
Baseline data (Demographic data, physical examination, cardiac function Rating (NYHA),6-minute walking distance);Routine examination (12-lead ECG, blood routine, biochemistry, BNP);Medication status (current medication);

Countries

China

Contacts

Public ContactChen Yucheng

West China Hospital of Sichuan University

chenyucheng2003@126.com+86 189 8060 2149

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026